Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) is highly expressed in liposarcoma and promotes migration and proliferation

Journal of Pathology

Volumn 224, Issue 4, 2011, Pages 575-588

  Wagner, Kay Dietrich ^a,b   Benchetrit, Maxime ^b,c   Bianchini, Laurence ^b   Michiels, Jean Franãois ^b,c   Wagner, Nicole ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d CNRS   (France)

Author keywords

leptin; liposarcoma; migration; peroxisome proliferator activated receptor; proliferation; transcriptional regulation

Indexed keywords

LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; SMALL INTERFERING RNA;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIPOMA; LIPOSARCOMA; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; LEPTIN; LIPOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PPAR DELTA; PPAR-BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 79960011498     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2910     Document Type: Article

References (43)

1. Weiss SW, Goldblum JR,. Enzinger & Weiss's Soft Tissue Tumours, 5th edn. Mosby Elsevier: Philadelphia, PA, 2008; 429-514.
2. Wagner KD, Wagner N,. Peroxisome proliferator-activated receptor β/δ (PPARβ/δ) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol Ther 2010; 125: 423-435.
3. Amri EZ, Bonino F, Ailhaud G, et al., Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. J Biol Chem 1995; 270: 2367-2371.
4. Chawla A, Schwarz EJ, Dimaculangan DD, et al., Peroxisome proliferator-activated receptor (PPAR)I: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798-800. (Pubitemid 24241266)
5. Grimaldi PA,. The roles of PPARs in adipocyte differentiation. Prog Lipid Res 2001; 40: 269-281. (Pubitemid 32544959)
6. Altiok S, Xu M, Spiegelman BM,. PPARI induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev 1997; 11: 1987-1998. (Pubitemid 27332985)
7. Jehl-Pietri C, Bastie C, Gillot I, et al., Peroxisome-proliferator- activated receptor-δ mediates the effects of long-chain fatty acids on post-confluent cell proliferation. Biochem J 2000; 350: 93-98.
8. Tontonoz P, Singer S, Forman BM, et al., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor-I and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237-241. (Pubitemid 27027193)
9. Demetri GD, Fletcher CD, Mueller E, et al., Induction of solid tumour differentiation by the peroxisome proliferator-activated receptor-I ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-3956. (Pubitemid 29169017)
10. Debrock G, Vanhentenrijk V, Sciot R, et al., A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-1412. (Pubitemid 37386592)
11. Italiano A, Bianchini L, Keslai F, et al., HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas, whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008; 122: 2233-2241. (Pubitemid 351542325)
12. Alexopoulou AN, Leao M, Caballero OL, et al., Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 2010; 12: R51.
13. Wagner N, Wagner KD, Theres H, et al., Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumour transcription factor Wt1. Genes Dev 2005; 19: 2631-2642. (Pubitemid 41565982)
14. Miller SG, De Vos P, Guerre-Millo M, et al., The adipocyte specific transcription factor C/EBPα modulates human ob gene expression. Proc Natl Acad Sci USA 1996; 93: 5507-11. (Pubitemid 26159480)
15. Fletcher CDM, Unni KK, Mertens F,. Pathology and Genetics of Tumours of Soft Tissue and Bone Soft Tissue Tumours. IARC Press: Lyon, 2002; 40-45.
16. Norton AJ, Jordan S, Yeomans P,. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994; 173: 371-379. (Pubitemid 24294106)
17. Bishop-Bailey D, Swales KE,. The role of PPARs in the endothelium: implications for cancer therapy. PPAR Res 2008; 2008: 904251.
18. Schote AB, Turner JD, Schiltz J, et al., Nuclear receptors in human immune cells: expression and correlations. Mol Immunol 2007; 44: 1436-1445. (Pubitemid 44415949)
19. Christy RJ, Yang VW, Ntambi JM, et al., Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer binding protein interacts with and activates the promoters of two adipocyte-specific genes. Genes Dev 1989; 3: 1323-1335.
20. Hu E, Tontonoz P, Spiegelman BM,. Transdifferentiation of myoblasts by the adipogenic transcription factors PPARI and C/EBPα. Proc Natl Acad Sci USA 1995; 92: 9856-9860.
21. Smas CM, Sul HS,. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993; 73: 725-734. (Pubitemid 23159011)
22. Ahima RS, Osei SY,. Leptin signaling. Physiol Behav 2004; 81: 223-241. (Pubitemid 38670089)
23. Poulos SP, Hausman DB, Hausman GJ,. The development and endocrine functions of adipose tissue. Mol Cell Endocrinol 2010; 323: 20-34.
24. Horvai AE, Schaefer JT, Nakakura EK, et al., Immunostaining for peroxisome proliferator-I distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas. Mod Pathol 2008; 21: 517-524. (Pubitemid 351589647)
25. Singer S, Socci ND, Ambrosini G, et al., Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67: 6626-6636. (Pubitemid 47105508)
26. Perez-Mancera PA, Bermejo-Rodriguez C, Sanchez-Martin M, et al., FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARI and C/EBPα and activating eIF4E. PLOS One 2008; 3: e2569.
27. Michalik L, Auwerx J, Berger JP, et al., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006; 58: 726-741. (Pubitemid 44833742)
28. Peters JM, Hollingshead HE, Gonzalez FJ,. Role of peroxisome- proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin Sci (Lond) 2008; 115: 107-127.
29. Wagner N, Jehl-Piétri C, Lopez P, et al., Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res 2009; 83: 61-71.
30. Michiels JF, Perrin C, Leccia N, et al., PPARβ activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1. Pflugers Arch 2010; 459: 689-703.
31. Peters JM, Gonzalez FJ,. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim Biophys Acta 2009; 1796: 230-241.
32. Peters JM, Lee SS, Li W, et al., Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol 2000; 20: 5119-5128. (Pubitemid 30431565)
33. Barak Y, Liao D, He W, et al., Effects of peroxisome proliferator- activated receptor-δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 303-308. (Pubitemid 34060358)
34. Catalano S, Mauro L, Marsico S, et al., Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor-α in MCF-7 cells. J Biol Chem 2004; 279: 19908-19915. (Pubitemid 38623433)
35. Onuma M, Bub JD, Rummel TL, et al., Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-42667. (Pubitemid 37310540)
36. Somasundar P, Yu AK, Vona-Davis L, et al., Differential effects of leptin on cancer in vitro. J Surg Res 2003; 113: 50-55. (Pubitemid 36999792)
37. Elinav E, Abd-Elnabi A, Pappo O, et al., Suppression of hepatocellular carcinoma growth in mice via leptin, is associated with inhibition of tumour cell growth and natural killer cell activation. J Hepatol 2006; 44: 529-536. (Pubitemid 43227877)
38. Aparicio T, Guilmeau S, Goiot H, et al., Leptin reduces the development of the initial precancerous lesions induced by azoxymethane in the rat colonic mucosa. Gastroenterology 2004; 126: 499-510. (Pubitemid 38182307)
39. Ablamuits V, Cohen Y, Brazee IB, et al., Susceptibility to induced and spontaneous carcinogenesis is increased in fatless A-ZIP/F1 but not in obese ob/ob mice. Cancer Res 2006; 66: 8897-8902. (Pubitemid 44449208)
40. Oliveira AM, Nascimento AG, Lloyd RV,. Leptin and leptin receptor mRNA are widely expressed in tumours of adipocytic differentiation. Mod Pathol 2001; 14: 549-555. (Pubitemid 32554078)
41. Wagoner B, Hausman DB, Harris RB,. Direct and indirect effects of leptin on preadipocyte proliferation and differentiation. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1557-15564.
42. Klimcakova E, Moro C, Mazzucotelli A, et al., Profiling of adipokines secreted from human subcutaneous adipose tissue in response to PPAR agonists. Biochem Biophys Res Commun 2007; 358: 897-902. (Pubitemid 46813132)
43. Shearer BG, Steger DJ, Way JM, et al., Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist. Mol Endocrinol 2008; 22: 523-529. (Pubitemid 351185947)